Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs 2014;31:1573-9. [PMID: 24077981 DOI: 10.1007/s10637-013-0020-2] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Accepted: 08/23/2013] [Indexed: 02/06/2023]

For:	Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X, Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study. Invest New Drugs 2014;31:1573-9. [PMID: 24077981 DOI: 10.1007/s10637-013-0020-2] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Accepted: 08/23/2013] [Indexed: 02/06/2023]

Number

Cited by Other Article(s)

Sabatelle RC, Colson YL, Sachdeva U, Grinstaff MW. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects. Mol Pharm 2024;21:3103-3120. [PMID: 38888089 PMCID: PMC11331583 DOI: 10.1021/acs.molpharmaceut.4c00246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/20/2024]

Choi KM, Kim B, Lee SM, Han J, Bae HS, Han SB, Lee D, Ham IH, Hur H, Kim E, Kim JY. Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts. Cell Commun Signal 2024;22:8. [PMID: 38167009 PMCID: PMC10763493 DOI: 10.1186/s12964-023-01396-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Accepted: 11/12/2023] [Indexed: 01/05/2024] Open

Abstract

BACKGROUND

Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment (TME) that play an important role in cancer progression. Although the mechanism by which CAFs promote tumorigenesis has been well investigated, the underlying mechanism of CAFs activation by neighboring cancer cells remains elusive. In this study, we aim to investigate the signaling pathways involved in CAFs activation by gastric cancer cells (GC) and to provide insights into the therapeutic targeting of CAFs for overcoming GC.

METHODS

Alteration of receptor tyrosine kinase (RTK) activity in CAFs was analyzed using phospho-RTK array. The expression of CAFs effector genes was determined by RT-qPCR or ELISA. The migration and invasion of GC cells co-cultured with CAFs were examined by transwell migration/invasion assay.

RESULTS

We found that conditioned media (CM) from GC cells could activate multiple receptor tyrosine kinase signaling pathways, including ERK, AKT, and STAT3. Phospho-RTK array analysis showed that CM from GC cells activated PDGFR tyrosine phosphorylation, but only AKT activation was PDGFR-dependent. Furthermore, we found that connective tissue growth factor (CTGF), a member of the CCN family, was the most pronouncedly induced CAFs effector gene by GC cells. Knockdown of CTGF impaired the ability of CAFs to promote GC cell migration and invasion. Although the PDGFR-AKT pathway was pronouncedly activated in CAFs stimulated by GC cells, its pharmacological inhibition affected neither CTGF induction nor CAFs-induced GC cell migration. Unexpectedly, the knockdown of SRC and SRC-family kinase inhibitors, dasatinib and saracatinib, significantly impaired CTGF induction in activated CAFs and the migration of GC cells co-cultured with CAFs. SRC inhibitors restored the reduced expression of epithelial markers, E-cadherin and Zonula Occludens-1 (ZO-1), in GC cells co-cultured with CAFs, as well as CAFs-induced aggregate formation in a 3D tumor spheroid model.

CONCLUSIONS

This study provides a characterization of the signaling pathways and effector genes involved in CAFs activation, and strategies that could effectively inhibit it in the context of GC. Video Abstract.

Collapse

Xu D, Luo Y, Wang P, Li J, Ma L, Huang J, Zhang H, Yang X, Li L, Zheng Y, Fang G, Yan P. Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer. Front Oncol 2023;13:1148131. [PMID: 37384288 PMCID: PMC10295723 DOI: 10.3389/fonc.2023.1148131] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 05/12/2023] [Indexed: 06/30/2023] Open

Zhang Y, Wang Z, Shen L, Li J, Huang J, Su W, Zhang D, Xu R. A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer. Cancer Commun (Lond) 2023;43:150-153. [PMID: 36331272 PMCID: PMC9859731 DOI: 10.1002/cac2.12379] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 09/02/2022] [Accepted: 10/20/2022] [Indexed: 11/06/2022] Open

Ryu MH, Lee KH, Shen L, Yeh KH, Yoo C, Hong YS, Park YI, Yang SH, Shin DB, Zang DY, Kang WK, Chung IJ, Kim YH, Ryoo BY, Nam BH, Park YS, Kang YK. Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE). Cancer Med 2022;12:7784-7794. [PMID: 36515003 PMCID: PMC10134272 DOI: 10.1002/cam4.5536] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 11/20/2022] [Accepted: 11/28/2022] [Indexed: 12/15/2022] Open

Abstract

BACKGROUND

In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first-line chemotherapy in advanced gastric cancer.

PATIENTS AND METHODS

Patients with metastatic gastric or gastroesophageal junction adenocarcinoma were randomized (1:1) to receive either sorafenib plus XP (S + XP) or XP alone. In cases of disease progression in the XP arm, crossover to sorafenib alone was allowed. The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), response rates, safety profiles, and biomarkers, and the response rates and PFS with secondline sorafenib alone after progression in the XP arm.

RESULTS

Between Jan 2011 and Feb 2013, a total of 195 patients were accrued (97 in the S + XP arm and 98 in the XP alone arm). The overall response rate was 54% with S + XP, and 52% with XP alone (p = 0.83). With a median follow-up of 12.6 months (range, 0.1-29.2), the median PFS assessed by independent review was 5.6 months in the S + XP arm and 5.3 months in the XP arm (hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.67-1.27, p = 0.61). Overall survival was not different between the two arms (median 11.7 vs. 10.8 months; HR 0.93, 95% CI 0.65-1.31, p = 0.66). Frequencies of grade 3/4 toxicities were similar between the S + XP and XP alone arms, except for neutropenia (21% vs. 37%), anorexia (0% vs. 5%), and hand-foot skin reaction (7% vs. 1%). Among 51 patients who crossed over to sorafenib alone after disease progression in the XP arm, there was no objective response and their median PFS was 1.3 months (95% CI, 1.2-1.7).

CONCLUSION

The addition of sorafenib to XP chemotherapy was safe but not more effective than XP alone for first-line treatment of metastatic gastric cancer.

Collapse

Affiliation(s)

Min-Hee Ryu Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Kyung Hee Lee Department of Hemato-oncology, Yeungnam University Hospital, Daegu, South Korea
Lin Shen Department of Gastrointestinal Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, China
Kun-Huei Yeh Department of Oncology, National Taiwan University Hospital; and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan
Changhoon Yoo Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Young Seon Hong Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea
Young Iee Park Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, South Korea
Sung Hyun Yang Department of Internal Medicine, Korea Cancer Center Hospital, Seoul, South Korea
Dong Bok Shin Division of Hematology/Oncology, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, South Korea
Dae Young Zang Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, South Korea
Won Ki Kang Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School Medicine, Seoul, South Korea
Ik-Joo Chung Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Gwangju, South Korea
Yeul Hong Kim Division of Hemato-Oncology, College of Medicine, Korea University, Anam Hospital, Seoul, South Korea
Baek-Yeol Ryoo Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Byung-Ho Nam Biometric Research Branch, National Cancer Center, Goyang, Gyeonggi, South Korea
Young Soo Park Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Yoon-Koo Kang Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Collapse

Haque E, Esmail A, Muhsen I, Salah H, Abdelrahim M. Recent Trends and Advancements in the Diagnosis and Management of Gastric Cancer. Cancers (Basel) 2022;14:5615. [PMID: 36428707 PMCID: PMC9688354 DOI: 10.3390/cancers14225615] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 11/10/2022] [Accepted: 11/10/2022] [Indexed: 11/17/2022] Open

Salati M, Caputo F, Bocconi A, Cerri S, Baldessari C, Piacentini F, Dominici M, Gelsomino F. Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma. Front Oncol 2022;12:993573. [PMID: 36212393 PMCID: PMC9540203 DOI: 10.3389/fonc.2022.993573] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Accepted: 08/23/2022] [Indexed: 11/13/2022] Open

Teneva T, Zlatarov A, Grigorov R. Role of Magnetic Resonance Imaging in Patients with Rectal Cancer. COLORECTAL CANCER 2021. [DOI: 10.5772/intechopen.94868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]

Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future. Anticancer Drugs 2021;32:593-601. [PMID: 33929995 DOI: 10.1097/cad.0000000000001071] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]

Houron C, Danielou M, Mir O, Fromenty B, Perlemuter G, Voican CS. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Crit Rev Oncol Hematol 2020;157:103127. [PMID: 33161366 DOI: 10.1016/j.critrevonc.2020.103127] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 09/29/2020] [Accepted: 10/05/2020] [Indexed: 12/24/2022] Open

Abstract

BACKGROUND

Multikinase inhibitors (MKI) are targeted molecular agents that have revolutionized cancer management. However, there is a paucity of data concerning MKI-related liver injury risk and clinical guidelines for the management of liver toxicity in patients receiving MKI for cancer are scarce.

DESIGN

We conducted a PubMed search of articles in English published from January 2000 to December 2018 related to hepatotoxicity of the 29 FDA-approved MKIs at doses used in clinical practice. The search terms were the international non-proprietary name of each agent cross-referenced with «hepatotoxicity», «hepatitis», «hepatic adverse event», or «liver failure», and «phase II clinical trial», «phase III clinical trial», or «case report».

RESULTS

Following this search, 140 relevant studies and 99 case reports were considered. Although asymptomatic elevation of aminotransferase levels has been frequently observed in MKI clinical trials, clinically significant hepatotoxicity is a rare event. In most cases, the interval between treatment initiation and the onset of liver injury is between one week and two months. Liver toxicity is often hepatocellular and less frequently mixed. Life-threatening MKI-induced hepatic injury has been described, involving fulminant liver failure or death. Starting from existing data, a description of MKI-related liver events, grading of hepatotoxicity risk, and recommendations for management are also given for various MKI molecules.

CONCLUSION

All MKIs can potentially cause liver injury, which is sometimes irreversible. As there is still no strategy available to prevent MKI-related hepatotoxicity, early detection remains crucial. The surveillance of liver function during treatment may help in the early detection of hepatotoxicity. Furthermore, the exclusion of potential causes of hepatic injury is essential to avoid unnecessary MKI withdrawal.

Collapse

Hsu A, Chudasama R, Almhanna K, Raufi A. Targeted therapies for gastroesophageal cancers. ANNALS OF TRANSLATIONAL MEDICINE 2020;8:1104. [PMID: 33145323 PMCID: PMC7576008 DOI: 10.21037/atm-20-3265] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 06/30/2020] [Indexed: 12/18/2022]

Hescheler DA, Plum PS, Zander T, Quaas A, Korenkov M, Gassa A, Michel M, Bruns CJ, Alakus H. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data. Gastric Cancer 2020;23:627-638. [PMID: 32107691 PMCID: PMC7305081 DOI: 10.1007/s10120-020-01045-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Accepted: 01/26/2020] [Indexed: 02/07/2023]

Hironaka S. Anti-angiogenic therapies for gastric cancer. Asia Pac J Clin Oncol 2019;15:208-217. [PMID: 31111678 DOI: 10.1111/ajco.13174] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Accepted: 05/07/2019] [Indexed: 12/12/2022]

Wen S, Shao G, Zheng J, Zeng H, Luo J, Gu D. Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling. Pathol Res Pract 2019;215:816-821. [PMID: 30686547 DOI: 10.1016/j.prp.2019.01.021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2018] [Revised: 01/02/2019] [Accepted: 01/17/2019] [Indexed: 12/31/2022]

Dahdaleh FS, Turaga KK. Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis. Surg Oncol Clin N Am 2018;27:519-537. [PMID: 29935687 DOI: 10.1016/j.soc.2018.02.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]

Bai ZG, Zhang ZT. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. Onco Targets Ther 2018;11:7077-7087. [PMID: 30410364 PMCID: PMC6200090 DOI: 10.2147/ott.s169484] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open

Abstract

Introduction

To date, anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb, bevacizumab), anti-VEGF receptor mAb (ramucirumab) and selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (sunitinib, sorafenib and apatinib) have been tested in the clinical trials.

Materials and methods

In the current study, results of 32 clinical trials (24 Phase I or II, 8 Phase III) were systematically reviewed and meta-analysis was performed in 8 Phase III trial results.

Results

It was found that median overall survival (OS) time and progression-free survival (PFS) time were significantly longer in the patients treated with antiangiogenic reagents compared to that in the patients with placebo when all of 8 Phase III clinical trials were analyzed together (OS: odds ratio = 0.805, 95% CI: 0.719–0.901, P < 0.001; PFS: odds ratio = 0.719, 95% CI: 0.533–969, P = 0.030).

Conclusion

Meta-analysis on bevacizumab (4 out 8 Phase III trials) indicated that neither OS nor PFS was significantly different between the groups treated with bevacizumab or placebo with or without combination of other chemotherapeutic reagents (OS: odds ratio = 0.909, 95% CI: 0.780–1.059, P = 0.221; PFS: odds ratio = 0.985, 95% CI: 0.865–1.122, P = 0.826). By contrast, meta-analysis on ramucirumab (3 out of 8 Phase III trials) revealed that ramucirumab was significantly favored in the treatment of gastric cancer with significant different OS between the two groups (odds ratio = 0.720, 95% CI: 0.604–0.858, P < 0.001). In addition, patients treated with VEGF or VEGFR blockers had higher morbidity of hypertension and neutropenia, but lower risk of side effects of vomiting and anemia. These findings suggest that addition of antiangiogenesis reagents, especially anti-VEGFR-mAb, to the first- or second-line chemotherapy could prolong patient’s OS and PFS time in the advanced or metastatic gastric cancer.

Collapse

Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther 2018;11:4137-4147. [PMID: 30050305 PMCID: PMC6056166 DOI: 10.2147/ott.s172305] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open

Gkolfinopoulos S, Papamichael D, Papadimitriou K, Papanastasopoulos P, Vassiliou V, Kountourakis P. Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients' decision making? World J Gastrointest Oncol 2018;10:172-183. [PMID: 30079143 PMCID: PMC6068857 DOI: 10.4251/wjgo.v10.i7.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Revised: 05/16/2018] [Accepted: 06/13/2018] [Indexed: 02/05/2023] Open

Abbas M, Faggian A, Sintali DN, Khan GJ, Naeem S, Shi M, Dingding C. Current and future biomarkers in gastric cancer. Biomed Pharmacother 2018;103:1688-1700. [DOI: 10.1016/j.biopha.2018.04.178] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 04/24/2018] [Accepted: 04/24/2018] [Indexed: 02/06/2023] Open

Kim S, Barzi A, Rajdev L. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. Semin Oncol 2018;45:133-150. [PMID: 30262395 DOI: 10.1053/j.seminoncol.2018.03.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Revised: 09/13/2017] [Accepted: 03/07/2018] [Indexed: 02/08/2023]

Ma JL, Zhang T, Suo FZ, Chang J, Wan XB, Feng XJ, Zheng YC, Liu HM. Lysine-specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC-803. J Cell Biochem 2018;119:4957-4966. [PMID: 29384217 DOI: 10.1002/jcb.26741] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 01/25/2018] [Indexed: 12/29/2022]

Affiliation(s)

Jin-Lian Ma Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China
Ting Zhang Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China
Feng-Zhi Suo Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China
Jiao Chang Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China
Xiang-Bin Wan Henan Cancer Hospital, Zhengzhou University, Zhengzhou, Henan, China
Xue-Jian Feng Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China
Yi-Chao Zheng Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China.,National Center for International Research of Micro-nano Molding Technology & Key Laboratory for Micro Molding Technology of Henan Province, Zhengzhou University, Zhengzhou, Henan, China
Hong-Min Liu Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China, Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, Henan, China

Collapse

Liu D, Ma X, Xiao D, Jia Y, Wang Y. Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis. Oncotarget 2018;9:8120-8132. [PMID: 29487720 PMCID: PMC5814287 DOI: 10.18632/oncotarget.23429] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2017] [Accepted: 11/29/2017] [Indexed: 12/21/2022] Open

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study. Sci Rep 2017;7:13208. [PMID: 29038432 PMCID: PMC5643341 DOI: 10.1038/s41598-017-13192-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 09/19/2017] [Indexed: 12/20/2022] Open

Chen LT, Oh DY, Ryu MH, Yeh KH, Yeo W, Carlesi R, Cheng R, Kim J, Orlando M, Kang YK. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Res Treat 2017;49:851-868. [PMID: 28052652 PMCID: PMC5654167 DOI: 10.4143/crt.2016.176] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Accepted: 12/20/2016] [Indexed: 02/08/2023] Open

Pinto MP, Owen GI, Retamal I, Garrido M. Angiogenesis inhibitors in early development for gastric cancer. Expert Opin Investig Drugs 2017;26:1007-1017. [PMID: 28770623 DOI: 10.1080/13543784.2017.1361926] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]

Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? Eur J Surg Oncol 2017;43:1835-1845. [PMID: 28888797 DOI: 10.1016/j.ejso.2017.08.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 08/02/2017] [Accepted: 08/10/2017] [Indexed: 02/06/2023] Open

Jin Z, Yoon HH. Antiangiogenic Therapy in Gastroesophageal Cancer. Hematol Oncol Clin North Am 2017;31:499-510. [PMID: 28501090 DOI: 10.1016/j.hoc.2017.01.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]

Panarese I, De Vita F, Ronchi A, Romano M, Alfano R, Di Martino N, Zito Marino F, Ferraraccio F, Franco R. Predictive biomarkers along gastric cancer pathogenetic pathways. Expert Rev Anticancer Ther 2017;17:417-425. [PMID: 28277834 DOI: 10.1080/14737140.2017.1301207] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]

Narita Y, Muro K. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. Expert Opin Drug Saf 2017;16:319-327. [PMID: 27976952 DOI: 10.1080/14740338.2017.1273348] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]

Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, Ajani JA. Advanced gastric adenocarcinoma: optimizing therapy options. Expert Rev Clin Pharmacol 2017;10:263-271. [PMID: 28094573 DOI: 10.1080/17512433.2017.1279969] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]

Mattina J, Carlisle B, Hachem Y, Fergusson D, Kimmelman J. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review. PLoS Biol 2017;15:e2000487. [PMID: 28158308 PMCID: PMC5291369 DOI: 10.1371/journal.pbio.2000487] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Accepted: 01/06/2017] [Indexed: 02/06/2023] Open

Abstract

Failure in cancer drug development exacts heavy burdens on patients and research systems. To investigate inefficiencies and burdens in targeted drug development in cancer, we conducted a systematic review of all prelicensure trials for the anticancer drug, sorafenib (Bayer/Onyx Pharmaceuticals). We searched Embase and MEDLINE databases on October 14, 2014, for prelicensure clinical trials testing sorafenib against cancers. We measured risk by serious adverse event rates, benefit by objective response rates and survival, and trial success by prespecified primary endpoint attainment with acceptable toxicity. The first two clinically useful applications of sorafenib were discovered in the first 2 efficacy trials, after five drug-related deaths (4.6% of 108 total) and 93 total patient-years of involvement (2.4% of 3,928 total). Thereafter, sorafenib was tested in 26 indications and 67 drug combinations, leading to one additional licensure. Drug developers tested 5 indications in over 5 trials each, comprising 56 drug-related deaths (51.8% of 108 total) and 1,155 patient-years (29.4% of 3,928 total) of burden in unsuccessful attempts to discover utility against these malignancies. Overall, 32 Phase II trials (26% of Phase II activity) were duplicative, lacked appropriate follow-up, or were uninformative because of accrual failure, constituting 1,773 patients (15.6% of 11,355 total) participating in prelicensure sorafenib trials. The clinical utility of sorafenib was established early in development, with low burden on patients and resources. However, these early successes were followed by rapid and exhaustive testing against various malignancies and combination regimens, leading to excess patient burden. Our evaluation of sorafenib development suggests many opportunities for reducing costs and unnecessary patient burden in cancer drug development.

Collapse

Pasini F, Fraccon AP, Modena Y, Bencivenga M, Giacopuzzi S, La Russa F, Gusella M, de Manzoni G. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? Gastric Cancer 2017;20:31-42. [PMID: 27568322 DOI: 10.1007/s10120-016-0626-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2016] [Accepted: 08/02/2016] [Indexed: 02/07/2023]

Yu J, Zhang Y, Leung LH, Liu L, Yang F, Yao X. Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. J Hematol Oncol 2016;9:111. [PMID: 27756337 PMCID: PMC5070169 DOI: 10.1186/s13045-016-0340-8] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Accepted: 10/08/2016] [Indexed: 01/05/2023] Open

Zhang XY, Zhang PY. Gastric cancer: somatic genetics as a guide to therapy. J Med Genet 2016;54:305-312. [PMID: 27609016 DOI: 10.1136/jmedgenet-2016-104171] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2016] [Accepted: 08/11/2016] [Indexed: 12/28/2022]

Ge S, Zhang Q, He Q, Zou J, Liu X, Li N, Tian T, Zhu Y, Gao J, Shen L. Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts. Oncol Lett 2016;12:1763-1768. [PMID: 27602110 PMCID: PMC4998225 DOI: 10.3892/ol.2016.4909] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Accepted: 06/29/2016] [Indexed: 12/18/2022] Open

Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol 2016;22:4812-23. [PMID: 27239108 PMCID: PMC4873874 DOI: 10.3748/wjg.v22.i20.4812] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2016] [Revised: 04/08/2016] [Accepted: 04/20/2016] [Indexed: 02/06/2023] Open

Roberto M, Romiti A, Onesti CE, Zullo A, Falcone R, Marchetti P. Evolving treatments for advanced gastric cancer: appraisal of the survival trend. Expert Rev Anticancer Ther 2016;16:717-29. [PMID: 27137418 DOI: 10.1080/14737140.2016.1184979] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]

Joo MK, Park JJ, Chun HJ. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management. World J Gastroenterol 2016;22:4638-4650. [PMID: 27217696 PMCID: PMC4870071 DOI: 10.3748/wjg.v22.i19.4638] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 04/01/2016] [Accepted: 04/20/2016] [Indexed: 02/06/2023] Open

Yuan DD, Zhu ZX, Zhang X, Liu J. Targeted therapy for gastric cancer: Current status and future directions (Review). Oncol Rep 2016;35:1245-54. [PMID: 26718131 DOI: 10.3892/or.2015.4528] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Accepted: 11/18/2015] [Indexed: 11/06/2022] Open

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol 2016;34:1448-54. [PMID: 26884585 DOI: 10.1200/jco.2015.63.5995] [Citation(s) in RCA: 709] [Impact Index Per Article: 78.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open

Affiliation(s)

Jin Li Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Shukui Qin Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Jianming Xu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Jianping Xiong Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Changping Wu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Yuxian Bai Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Wei Liu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Jiandong Tong Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Yunpeng Liu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Ruihua Xu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Zhehai Wang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Qiong Wang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Xuenong Ouyang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Yan Yang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Yi Ba Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Jun Liang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Xiaoyan Lin Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Deyun Luo Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Rongsheng Zheng Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Xin Wang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Guoping Sun Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Liwei Wang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Leizhen Zheng Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Hong Guo Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Jingbo Wu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Nong Xu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Jianwei Yang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Honggang Zhang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Ying Cheng Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Ningju Wang Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Lei Chen Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Zhining Fan Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Piaoyang Sun Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun
Hao Yu Jin Li, Fudan University Shanghai Cancer Center; Liwei Wang, Shanghai First People's Hospital; Leizhen Zheng, XinHua Hospital Affiliated to Shanghai Jiaotong University, Shanghai; Shukui Qin, People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Zhining Fan, Second Affiliated Hospital of Nanjing Medical University; Hao Yu, Nanjing Medical University, Nanjing; Jianming Xu, 307th Hospital of PLA, Academy of Military Medical Sciences; Honggang Zhang, Chinese Academy of Medical Sciences Cancer Hospital, Beijing; Jianping Xiong, First Affiliated Hospital of Nanchang University, Nanchang; Changping Wu, First People's Hospital of Changzhou, Changzhou; Yuxian Bai, Harbin Medical University Cancer Hospital, Harbin; Wei Liu, Hebei Medical University Fourth Hospital, Hebei Provincial Tumor Hospital, Shijiazhuang; Jiandong Tong, Yangzhou No. 1 People's Hospital, Yangzhou; Yunpeng Liu, First Hospital of China Medical University, Shenyang; Ruihua Xu, Sun Yat-Sen University Cancer Center, Guangzhou; Zhehai Wang, Shandong Cancer Hospital, Jinan; Qiong Wang, Jiangsu Jiangyin People's Hospital, Jiangyin; Xuenong Ouyang, Fuzhou General Hospital of Nanjing Military Command; Jianwei Yang, Fujian Provincial Cancer Hospital, Fuzhou; Yan Yang, Gansu Cancer Hospital, Lanzhou; Yi Ba, Tianjin Medical University Cancer Institute and Hospital, Tianjin; Jun Liang, Affiliated Hospital of Qingdao University, Qingdao; Xiaoyan Lin, Fujian Medical University Union Hospital, Fujian; Deyun Luo, West China Hospital, Sichuan University, Chengdu; Rongsheng Zheng, First Affiliated Hospital of Bengbu Medical College, Bengbu; Xin Wang, Xijing Hospital, Xi'an; Guoping Sun, First Affiliated Hospital of Anhui Medical University, Hefei; Hong Guo, Xinqiao Hospital, Third Military Medical University, Chongqing; Jingbo Wu, Affiliated Hospital of Luzhou Medical College, Luzhou; Nong Xu, First Affiliated Hospital of Zhejiang University, Hangzhou; Ying Cheng, Jilin Provincial Cancer Hospital, Changchun

Collapse

Aguiar PN, Muniz TP, Miranda RR, Tadokoro H, Forones NM, Monteiro IDP, Castelo-Branco P, Janjigian YY, De Mello RA. Current advances in targeted therapies for metastatic gastric cancer: improving patient care. Future Oncol 2016;12:839-54. [PMID: 26838766 DOI: 10.2217/fon.15.348] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open

Roviello G, Petrioli R, Marano L, Polom K, Marrelli D, Perrella A, Roviello F. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer 2016;19:31-41. [PMID: 26329368 DOI: 10.1007/s10120-015-0537-5] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2015] [Accepted: 08/15/2015] [Indexed: 02/07/2023]

Shan F, Miao R, Xue K, Li Z, Li Z, Bu Z, Wu A, Zhang L, Wu X, Zong X, Wang X, Li S, Ji X, Jia Z, Li Z, Ji J. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials. Cancer Lett 2015;380:598-607. [PMID: 26724681 DOI: 10.1016/j.canlet.2015.12.023] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Revised: 12/15/2015] [Accepted: 12/16/2015] [Indexed: 12/31/2022]

Affiliation(s)

Fei Shan Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Rulin Miao Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Kan Xue Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Zhemin Li Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Ziyu Li Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Zhaode Bu Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Aiwen Wu Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Lianhai Zhang Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Xiaojiang Wu Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Xianglong Zong Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Xiaohong Wang Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Shuangxi Li Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Xin Ji Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Ziyu Jia Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Ziran Li Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China
Jiafu Ji Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, Beijing 100142, China.

Collapse

Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol 2015;21:11621-35. [PMID: 26556991 PMCID: PMC4631965 DOI: 10.3748/wjg.v21.i41.11621] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 08/14/2015] [Accepted: 09/30/2015] [Indexed: 02/06/2023] Open

Woo J, Cohen SA, Grim JE. Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep (Oxf) 2015;3:316-29. [PMID: 26510453 PMCID: PMC4650980 DOI: 10.1093/gastro/gov052] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Accepted: 09/09/2015] [Indexed: 12/12/2022] Open

Janjigian YY, Vakiani E, Ku GY, Herrera JM, Tang LH, Bouvier N, Viale A, Socci ND, Capanu M, Berger M, Ilson DH. Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS One 2015;10:e0134731. [PMID: 26275293 PMCID: PMC4537304 DOI: 10.1371/journal.pone.0134731] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Accepted: 07/11/2015] [Indexed: 12/19/2022] Open

Affiliation(s)

Yelena Y. Janjigian Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
Efsevia Vakiani Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States of America
Geoffrey Y. Ku Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
Jessica M. Herrera Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America
Laura H. Tang Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States of America
Nancy Bouvier Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America
Agnès Viale Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America
Nicholas D. Socci Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America Departments of Bioinformatics, Sloan Kettering Institute, New York, United States of America
Marinela Capanu Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, United States of America
Michael Berger Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, United States of America Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Sloan Kettering Institute, New York, United States of America
David H. Ilson Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, United States of America

Collapse

Dahle-Smith A, Petty RD. Biomarkers and novel agents in esophago-gastric cancer: are we making progress? Expert Rev Anticancer Ther 2015;15:1103-19. [DOI: 10.1586/14737140.2015.1071669] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]

Vincenzi B, Imperatori M, Silletta M, Marrucci E, Santini D, Tonini G. Emerging kinase inhibitors of the treatment of gastric cancer. Expert Opin Emerg Drugs 2015;20:479-93. [PMID: 26021342 DOI: 10.1517/14728214.2015.1051467] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]

Chi Y, Yang J, Yang S, Sun Y, Jia B, Shi Y. Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer. Chin J Cancer Res 2015;27:239-46. [PMID: 26157320 PMCID: PMC4490194 DOI: 10.3978/j.issn.1000-9604.2015.06.08] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 06/03/2015] [Indexed: 12/22/2022] Open

Murphy A, Kelly RJ. From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer. Gastroenterol Res Pract 2015;2015:896560. [PMID: 25784931 PMCID: PMC4346691 DOI: 10.1155/2015/896560] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2014] [Accepted: 01/15/2015] [Indexed: 01/14/2023] Open